US FDA’s Patent ‘Concerns’ Include Thickets, Product Hopping, And Evergreening

With a report due to Congress in January, Orange Book patent issues may find their way into user fee reauthorization legislation next year. • Source: Nielsen Hobbs

More from Legal & IP

More from Pink Sheet